Lima, Ana Rita http://orcid.org/0000-0003-1439-770X
Pinto, Joana http://orcid.org/0000-0001-9719-8364
Azevedo, Ana Isabel
Barros-Silva, Daniela http://orcid.org/0000-0001-6746-6807
Jerónimo, Carmen http://orcid.org/0000-0003-4186-5345
Henrique, Rui http://orcid.org/0000-0003-3171-4666
de Lourdes Bastos, Maria http://orcid.org/0000-0001-9895-503X
Guedes de Pinho, Paula http://orcid.org/0000-0002-7395-5700
Carvalho, Márcia http://orcid.org/0000-0001-9884-4751
Article History
Received: 20 May 2019
Revised: 21 August 2019
Accepted: 4 September 2019
First Online: 7 October 2019
Competing interests
: The authors declare no competing interests.
: The study was approved by the Portuguese Oncology Institute of Porto (IPO Porto) Ethics Committee (reference number: 282 R/2017) and conducted in accordance with the Declaration of Helsinki. All subjects included in the study provided informed consent at the time of enrolment.
: This work received financial support from the European Union (FEDER funds POCI/01/0145/FEDER/007728) and National Funds (FCT/MEC, Fundação para a Ciência e a Tecnologia and Ministério da Educação e Ciência) under the Partnership Agreement PT2020 UID/MULTI/04378/2013. The study is a result of the project NORTE-01–0145-FEDER-000024, supported by Norte Portugal Regional Operational Programme (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement (DESignBIOtecHealth-New Technologies for three Health Challenges of Modern Societies: Diabetes, Drug Abuse and Kidney Diseases), through the European Regional Development Fund (ERDF). A.R.L. was the recipient of a PhD fellowship from FCT (SFRH/BD/123012/2016) and M.C. acknowledges financial support from FCT through the UID/MULTI/04546/2019 project.
: Not applicable.
: All data that support the findings of this study are included in this published article and its InternalRef removed files.